ConductScience.org, home

Comparison · NCT06634797-6e547093

mRNA-1273.712 vs Placebo: Number of Participants With Elevated cTnI Level at Day 29 or Day 57 (28 Days After Injection 1 or Injection 2)

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. mRNA-1273.712 vs Placebo: Number of Participants With Elevated cTnI Level at Day 29 or Day 57 (28 Days After Injection 1 or Injection 2). Trial comparisons, record NCT06634797-6e547093. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT06634797-6e547093

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.004660.001810.0119wilson
Risk in group 20.009380.004760.0184wilson
Risk difference, group 1 minus group 2-0.00472-0.01420.00389newcombe hybrid score
Risk ratio, group 1 over group 20.4970.151.64log
Odds ratio, group 1 over group 20.4950.1481.65log
Number needed to treat, for one fewer participant with the outcome on mRNA-1273.712 than on Placebo212from the risk difference intervalthe interval includes no difference

Groups2

Group 2 names the comparator: placebo.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1mRNA-1273.712Participants received mRNA-1273.712 as an IM injection on either Day 1 in Sequence 1 (mRNA-1273.712 - placebo) or Day 29 in Sequence 2 (placebo - mRNA-1273.712) of the study.4858OG000
Group 2PlaceboParticipants received placebo matched to mRNA-1273.712 as an IM injection on either Day 1 in Sequence 2 (placebo - mRNA-1273.712) or Day 29 in Sequence 1 (mRNA-1273.712 - placebo) of the study.8853OG001

Outcome

Type
SECONDARY
Title
Number of Participants With Elevated cTnI Level at Day 29 or Day 57 (28 Days After Injection 1 or Injection 2)
Description
Elevated cTnI was defined as \>53.53 pg/mL in males and \>38.64 pg/mL in females.
Time frame
Day 29 and Day 57
Population
Evaluable Set: All randomized participants who received at least 1 study injection who had no major protocol deviations or conditions/medications that impacted critical or key analysis data. The 'number of participants analysed' includes the number of participants with normal cTnI at pre-injection and non-missing cTnI at both pre-injection and 28 days after any injection.

Source ClinicalTrials.gov

Trial

Title
A Study to Investigate Cardiac Troponin Levels After mRNA-1273.712 Vaccine in Participants 12 Through 30 Years of Age
NCT number
NCT06634797
Phases
PHASE4
Conditions
Healthy Volunteers
Interventions
mRNA-1273.712, Placebo
Lead sponsor
ModernaTX, Inc.
Results first posted
2026-02-04

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT06634797-6e547093